Apnimed, Inc. (NASDAQ:APMD – Get Free Report) shares reached a new 52-week low during trading on Monday. The stock traded as low as $16.12 and last traded at $16.37, with a volume of 130,191 shares. The stock had previously closed at $16.40.
Analyst Ratings Changes
A number of research analysts recently weighed in on the stock. Lifesci Capital started coverage on shares of Apnimed in a research note on Tuesday, August 25th. They issued an “outperform” rating and a $50.00 price objective for the company. Cantor Fitzgerald assumed coverage on Apnimed in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 target price on the stock. Evercore started coverage on Apnimed in a report on Tuesday, August 25th. They issued an “outperform” rating for the company. Wall Street Zen upgraded Apnimed to a “hold” rating in a research report on Saturday, August 8th. Finally, Bank of America assumed coverage on Apnimed in a research note on Tuesday, August 25th. They set a “buy” rating and a $41.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.33.
Read Our Latest Research Report on Apnimed
Apnimed Stock Performance
Apnimed (NASDAQ:APMD – Get Free Report) last posted its earnings results on Tuesday, September 8th. The company reported $0.51 earnings per share (EPS) for the quarter. The firm had revenue of $12.08 million during the quarter. Equities analysts predict that Apnimed, Inc. will post -0.24 earnings per share for the current year.
Apnimed Company Profile
Apnimed Inc is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA). The company is developing oral therapies intended to address the underlying physiological causes of OSA rather than relying solely on mechanical devices such as continuous positive airway pressure machines.
Apnimed’s lead program is AD109, an investigational once-daily oral therapy designed to improve upper-airway muscle activity during sleep.
See Also
- Five stocks we like better than Apnimed
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
